HROW
Drug Manufacturers - Specialty & Generic · Healthcare
CFO
Equibles does not estimate personal net worth.
Get an email with a short summary when Harrow, Inc. publishes a filing, an earnings call transcript or a press release.
Get HROW alertsAndrew Boll is recorded as CFO at Harrow, Inc. (HROW). The proxy statement of Harrow, Inc. reports total compensation of $10,947,441 for Andrew Boll in fiscal 2025, including a base salary of $505,259. Disclosed compensation is on record for 7 fiscal years. Andrew Boll has spoken on 19 earnings calls across 1 company, most recently for Harrow, Inc. on November 10, 2026. Harrow, Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Harrow, Inc. includes Francis W. Mullery (CEO), Frank Mullery (CEO), John P. Saharek (CEO) and 7 others.
“Third quarter revenue was a record $99.3 million, up 41% sequentially and 39% year-over-year. Branded revenue was $83.5 million, up about 62% year-over-year, and made up roughly 84% of total revenue.”
“For the first quarter of 2026, we reported consolidated revenues of $44.2 million and adjusted EBITDA of negative $12.7 million. As we previously communicated, Q1 was expected to be the lowest revenue quarter of the year.”
“And thank you to everyone joining the call today. Turning now to our financial performance. Total revenue for the third quarter was $71.6 million, representing a 45% increase over the same period in 2024 and a 12% sequential increase from the second quarter of this year.”
“Yes, I think it's best to look at it on a forward-looking basis regarding unit volume and demand. We've observed a similar trend between Q4 and Q1 in the past, specifically with IHEEZO showing some softness in unit demand.”
“Yes, Chase, I think from our perspective, too, we are obviously early in the game with the relaunch, so it is a little early for us to give more precise guidance on what we think the exact pull-through will be, but the initial response has been great.”
HROW
Drug Manufacturers - Specialty & Generic · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Harrow, Inc. (HROW) | CFO | $505,259 | $10,947,441 |
| 2024 | Harrow, Inc. (HROW) | CFO | $491,920 | $849,201 |
| 2023 | Harrow, Inc. (HROW) | CFO | $459,900 | $7,130,409 |
| 2022 | Harrow, Inc. (HROW) | CFO | $416,427 | $764,386 |
| 2021 | Harrow, Inc. (HROW) | CFO | $405,073 | $3,352,154 |
| 2020 | Harrow, Inc. (HROW) | CFO | $409,655 | $1,016,804 |
| 2019 | Harrow, Inc. (HROW) | CFO | $348,391 | $1,049,545 |